GENZYME CORPORATION for GENZYME CORPORATION

Taxation/Internal Revenue Code TAX

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012 Tax Reform

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues AHRQ Studies of Orphan DrugsDrug Supply Chain Security H.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Quality, Security, and Accountability Act H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1128 (113th), H.R. 2315 (113th), H.R. 1281 (113th), H.R. 1919 (113th), S. 959 (113th), S. 1417 (113th)

Medicare/Medicaid MMM

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 S. 1871, Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1516 (113th), H.R. 413 (113th), H.R. 800 (113th), S. 117 (113th), S. 77 (113th), S. 1871 (113th), H.R. 4302 (113th)

Budget/Appropriations BUD

FY 2014 Budget Funding for FDA and NIH FY 2015 Budget

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Pharmacy PHA

Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal S. 959, Pharmaceutical Quality, Security, and Accountability Act S. 957, Drug Supply Chain Security ActH.R. 1919, Safeguarding Americas Pharmaceuticals Act of 2013

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 959 (113th), S. 957 (113th)